Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray

Figure 2

Analysis of the relationship between ICAM1 mRNA expression and prognosis of patients with serous ovarian carcinoma based on TCGA (a) and TCGA/GEO (b, c, d) datasets. (a) Patients with ICAM1 mRNA overexpression had shorter overall survival than those with low ICAM1 mRNA expression (P < 0.05). (b, c) Serous ovarian carcinoma (SOC) patients with ICAM1 mRNA overexpression treated with chemotherapeutic drugs that contained taxol or taxol and platin together had shorter progression-free survival (P < 0.01 for both). (d) There was no significant difference in progression-free survival for the SOC patient group that was treated with chemotherapeutic drugs which contained platin (P > 0.05).

(a)

(b)

(c)

(d)